about
In vitro aspirin resistance detected by PFA-100 closure time: pivotal role of plasma von Willebrand factorQuantification of risk factors for venous thromboembolism: a preliminary study for the development of a risk assessment toolAn update on prevention of venous thromboembolism in hospitalized acutely ill medical patientsEffective hemostasis with rFVIIa treatment in two patients with severe thrombocytopenia and life-threatening hemorrhage.On the mechanism of action of recombinant activated factor VII administered to patients with severe thrombocytopenia and life-threatening haemorrhage: focus on prothrombin activation.Biochemistry and clinical pharmacology of new anticoagulant agents.Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesThe mechanism of action of rivaroxaban--an oral, direct Factor Xa inhibitor--compared with other anticoagulants.Synthetic direct and indirect factor Xa inhibitors.New antithrombotic drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesIs the inhibition of both clot-associated thrombin and factor Xa more clinically relevant than either one alone?Newer anticoagulants in 2009.The significance of endothelial heterogeneity in thrombosis and hemostasis.Assays for measuring rivaroxaban: their suitability and limitations.Use of low-molecular-weight heparins and new anticoagulants in elderly patients with renal impairment.Massive transfusion: an overview of the main characteristics and potential risks associated with substances used for correction of a coagulopathy.Laboratory testing of rivaroxaban in routine clinical practice: when, how, and which assays.Laboratory assessment of rivaroxaban: a review.Pharmacology and laboratory testing of the oral Xa inhibitors.Inhibition of factor VIIa generation and prothrombin activation by treatment with enoxaparin in patients with unstable angina.In vitro effect of melagatran and lepirudin on clot-bound thrombin.Correlation of plasma coagulation parameters with thromboprophylaxis, patient characteristics, and outcome in the MEDENOX study.Assessment of laboratory assays to measure rivaroxaban--an oral, direct factor Xa inhibitor.
P50
Q28166489-F9C12F33-3628-4D89-ADD3-1B3B12DCDCC1Q28166566-D4788DB5-F626-4A94-ABA8-992433341D01Q28198905-17635854-DA91-4D93-832C-18B652B49F72Q33341446-2528A340-5149-476F-80A7-DBCEA9655CB4Q33342552-E3CFFEEE-D1E6-4DF2-B69B-7D78DC84C624Q33352798-49CAD5B8-7089-44B3-B97B-24EFC639B964Q33399576-CD42C7C1-3709-4D99-AF9D-7DCE1F053F5FQ34624001-5A89922C-71B0-44B9-8B64-7A44C855F490Q34924749-0FA66A65-6341-417F-AB4E-DB0AF3A8A107Q35752611-2852BE4A-BA52-4721-973D-28C4ACFFD246Q37573373-BF2ED140-B9DB-4EAA-996E-E0DBA7284059Q37617159-158F0FD3-07A0-4EC0-B2A7-4957615F7714Q37758582-279690A7-522A-4151-B3A2-008B351B5497Q37789142-8D06E28B-9B0A-4D53-9E0E-85F8237E0BE5Q37844143-B3DD2A67-1435-4D41-A48F-CB61B30F1425Q38024467-011572EF-0FC5-4BB9-8926-5E1E26050717Q38112792-BBC08624-3129-42F3-BE4C-E49B281708A1Q38119016-C99DC2D8-7816-4CDA-A79A-7D8D26969A9FQ38244367-C695843C-595D-4790-8BAB-A808C9A00C92Q44316593-D0DC1F03-1A5B-4D3E-BF08-150468448397Q44598003-E495CE4B-A591-4ED3-A950-C3039540CDBBQ44845827-51AF6A02-E7DF-40D4-B892-02FDC4105CB4Q50234462-57C95306-3AE6-414A-AD8D-6573A4A577C5
P50
name
Meyer Michel Samama
@ast
Meyer Michel Samama
@en
Meyer Michel Samama
@es
Meyer Michel Samama
@nl
type
label
Meyer Michel Samama
@ast
Meyer Michel Samama
@en
Meyer Michel Samama
@es
Meyer Michel Samama
@nl
prefLabel
Meyer Michel Samama
@ast
Meyer Michel Samama
@en
Meyer Michel Samama
@es
Meyer Michel Samama
@nl